HEMORRHOIDAL EMBOLIZATION TRIAL

Overview

About this study

The  purpose of this study is to determine the 12-month safety and effiectiveness of rectal artery embolization with particles + coils for treatment of symptomatic bleeding predominant hemorrhoidal disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age: 18-90.
  • Grade II or III hemorrhoidal disease as determined by a board-certified colorectal surgeon.
  • Persistent or recurrent symptoms following hygiene and dietary measures or medication.
  • Bleeding predominant ± pain symptoms.
  • Undergoing planned rectal artery embolization (RAE) per standard clinical care.
  • Male or female with age greater than 18 years, with the capacity and willingness to provide a written informed consent.
  • Negative pregnancy test (if applicable).

Exclusion Criteria:

  • Prior hemorrhoid surgery.
  • Grade IV hemorrhoidal disease.
  • Acute hemorrhoid complications.
  • Chronic anal or perianal fissures.
  • History of colorectal surgery or pelvic radiation.
  • Inflammatory bowel disease.
  • Portal hypertension or mesenteric venous congestion/occlusion.
  • Inferior mesenteric artery (IMA) or internal iliac artery (IIA) stenosis or occlusion.
  • Contraindication to iodinated contrast.
  • Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of the procedure per clinical care.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Scott Thompson, M.D., Ph.D.

Contact us for the latest status

Contact information:

Desirae Howe-Clayton

Howe.Desirae@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20556753

Mayo Clinic Footer